218 related articles for article (PubMed ID: 30941515)
1. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
Hu R; Winter A; Hill BT
Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
5. The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.
Camus V; Jardin F; Tilly H
Expert Rev Mol Diagn; 2017 Jun; 17(6):557-566. PubMed ID: 28415895
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
[TBL] [Abstract][Full Text] [Related]
7. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
Heger JM; d'Hargues Y; Kleinert F; Mattlener J; Weiss J; Franzen F; Becker C; Becker K; Gödel P; Schmiel M; Meinel J; Flümann R; Simon F; Reinhardt HC; Borchmann P; Borchmann S; Balke-Want H; Knittel G; von Tresckow B
Eur J Haematol; 2024 Jun; 112(6):957-963. PubMed ID: 38369814
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
11. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
Melani C; Wilson WH; Roschewski M
Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
Kurtz DM; Green MR; Bratman SV; Scherer F; Liu CL; Kunder CA; Takahashi K; Glover C; Keane C; Kihira S; Visser B; Callahan J; Kong KA; Faham M; Corbelli KS; Miklos D; Advani RH; Levy R; Hicks RJ; Hertzberg M; Ohgami RS; Gandhi MK; Diehn M; Alizadeh AA
Blood; 2015 Jun; 125(24):3679-87. PubMed ID: 25887775
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma.
Hagiwara K; Li Y; Kinoshita T; Kunishma S; Ohashi H; Hotta T; Nagai H
Leuk Res; 2010 Jan; 34(1):50-4. PubMed ID: 19616848
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy in tissue-born lymphomas.
Spina V; Rossi D
Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
16. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
[TBL] [Abstract][Full Text] [Related]
17. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
18. Measurable Residual Disease Monitoring in Lymphoma.
Cuzzo B; Lipsky A; Cherng HJ
Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
Chase ML; Armand P
Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
[TBL] [Abstract][Full Text] [Related]
20. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
